NEI Regenerative Medicine Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed)
ID: 338605Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $150K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/338605

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-135.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the NEI Regenerative Medicine Clinical Trial Planning Grant (R34), aimed at supporting the planning stages of clinical trials focused on regenerative medicine interventions to restore vision in humans. This grant provides funding for the development of essential protocols and a Manual of Procedures (MOP) necessary for initiating clinical trials, although it does not fund the trials themselves. With a funding ceiling of $150,000 available annually for a maximum of two years, applications will be evaluated based on scientific merit criteria, and the deadline for submission is May 7, 2025. Interested applicants can find more information and contact details at the NIH website or via email at OERWebmaster03@od.nih.gov.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-135-Full-Announcement.html
    PAR-22-135.html
    The National Eye Institute (NEI) of the National Institutes of Health (NIH) issued a Funding Opportunity Announcement (FOA) for the NEI Regenerative Medicine Clinical Trial Planning Grant (R34). This grant is aimed at supporting the planning stages of clinical trials focused on regenerative medicine interventions designed to restore vision in humans. Eligible applicants include higher education institutions, non-profit organizations, and government entities. The grant covers the development of a Manual of Procedures (MOP) and essential protocols for initiating clinical trials. Funding up to $150,000 is available annually for a maximum of two years, with applications reviewed based on various scientific merit criteria. The primary purpose is to facilitate crucial preliminary activities such as regulatory approvals and collaborative arrangements necessary for phased clinical trials in the regenerative field. The grant specifically does not fund clinical trials themselves but is essential for documenting feasibility and safety data to meet FDA requirements for future trials. Applications are evaluated by scientific review groups and should illustrate clear strategies, milestones, and administrative capabilities. The expiration of this grant opportunity is set for May 8, 2025.
    Similar Opportunities
    NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NEI Clinical Research Study Planning Grant Program (R34), aimed at supporting the development of clinical trial protocols and procedures specifically for eye and vision-related studies. This grant facilitates the preparation of a comprehensive Manual of Procedures (MOP) and allows for preliminary studies to assess recruitment potential, without generating data on intervention effects. Grants may provide up to $150,000 per year for a maximum of two years, with applications due by May 7, 2025. Eligible applicants include a wide range of institutions, including educational, nonprofit, and government entities, and inquiries can be directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled the NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed) aimed at accelerating the translation of innovative laboratory research into therapeutic interventions for visual system diseases. This program employs a bi-phasic, milestone-driven mechanism consisting of an Exploratory (R61) phase lasting up to two years and a Developmental (R33) phase lasting up to three years, focusing on generating preclinical data that supports applications for Investigational New Drug (IND) or Investigational Device Exemption (IDE) submissions to the FDA. The initiative is designed to engage diverse organizations, including historically black colleges, tribal governments, and community-based organizations, to foster collaborative efforts in ocular research, ultimately improving health outcomes through vision research. Interested applicants can find more information and guidelines at the provided link, with a funding ceiling of $500,000 and a submission deadline of March 16, 2025.
    NEI Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Eye Institute (NEI) for cooperative agreements (U01) aimed at supporting early-stage clinical trials that involve greater than minimal risk, specifically targeting interventions for vision disorders. This initiative encourages applications for Phase I or II trials that are backed by strong preliminary data and require compliance with NIH guidelines, including the establishment of a Data Monitoring and Safety Committee (DSMC) for safety oversight. The funding is crucial for advancing research in the screening, diagnosis, prevention, and treatment of vision disorders, with project budgets reflecting actual needs and a maximum project period of five years. Interested applicants can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with the application deadline set for May 7, 2025.
    NEI Translational Research Program for Therapeutics (R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NEI Translational Research Program for Therapeutics, aimed at accelerating the translation of innovative laboratory research into therapeutics for visual system diseases. This program seeks to fund multidisciplinary teams that can generate preclinical data leading to Investigational New Drug (IND) or Investigational Device Exemption (IDE) applications, with a focus on developing biological, pharmacological, and medical device interventions. The initiative underscores the federal commitment to translating biomedical research into practical therapies, ultimately enhancing patient care in ocular health. Grants of up to $1 million per year are available, with applications due by March 16, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NEI Collaborative Clinical Vision Research Project: Resource Center Grant (UG1 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NEI Collaborative Clinical Vision Research Project, specifically for Resource Center Grants (UG1 Clinical Trial Required). This initiative aims to support large-scale clinical trials focused on screening, diagnosing, preventing, or treating vision disorders, with a particular emphasis on evaluating complex interventions and providing essential services for multi-center trials. The NEI seeks to advance vision health through rigorous research, and applications are encouraged from a diverse range of eligible applicants, including various educational institutions and organizations. Interested parties must submit their applications by May 25, 2026, and can find additional information and guidelines at NIH Grants. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NEI Collaborative Clinical Vision Research Project, specifically seeking applications for a Coordinating Center grant under the UG1 activity code. This initiative aims to support large-scale, investigator-initiated clinical trials focused on vision disorders, including interventions for screening, diagnosing, preventing, or treating these conditions, with an emphasis on projects that require significant oversight and management. The NEI's mission is to advance vision research and enhance public health through rigorous clinical trials, ensuring compliance with NIH policies and ethical standards in research involving human subjects. Interested applicants, including a diverse range of organizations such as higher education institutions and nonprofits, must submit their applications by May 25, 2026, and can find further details at the provided NIH grants information email: grantsinfo@nih.gov.
    NEI Collaborative Clinical Vision Research: Chair's Grant (UG1-Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Eye Institute (NEI), has announced a Notice of Funding Opportunity (NOFO) for the NEI Collaborative Clinical Vision Research: Chair's Grant (UG1), aimed at supporting large-scale clinical trials focused on vision disorders. This funding opportunity is intended for projects that evaluate interventions for screening, diagnosing, preventing, or treating vision disorders, specifically requiring a clinical trial with a clear scientific rationale and detailed study design. The NEI emphasizes the importance of these trials in advancing vision science and public health, with awards structured as cooperative agreements to ensure substantial NIH involvement in the research process. Interested applicants must submit their proposals by May 25, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Eye Institute (NEI), is inviting applications for the NEI Research Grant for Vision-Related Secondary Data Analysis (R21), which focuses on funding innovative research projects that utilize existing vision-related datasets for secondary data analyses. This opportunity aims to enhance understanding of vision health issues by encouraging researchers to leverage data from previous clinical trials or epidemiologic studies, while explicitly excluding support for new data collection. Eligible applicants include a wide range of institutions, such as historically black colleges and universities, tribal colleges, and community-based organizations, with a direct cost ceiling of $275,000 for projects lasting up to two years. Interested parties should submit their applications by May 7, 2025, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further information.
    NEI Center Core Grant for Vision Research (P30 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NEI Center Core Grant for Vision Research, aimed at enhancing collaborative vision research through shared resource and service cores for funded investigators. This grant supports institutions with eight or more active NEI-supported R01 grants, providing direct costs of up to $2 million or $2.5 million over five years, depending on the number of eligible grants at the institution. The program is designed to increase productivity and collaboration among researchers while offering high-quality services that would be too costly for individual projects, ultimately supporting the NEI's mission to advance understanding of vision disorders. Applications are due by September 30, 2023, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44-Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44), aimed at supporting small business concerns (SBCs) conducting early-stage clinical trials related to vision disorders. Applicants are required to propose studies that evaluate interventions for screening, diagnosing, preventing, or treating eye diseases, with a focus on trials that typically fall under Phase I or II and involve greater than minimal risk, necessitating appropriate oversight and safety monitoring. This initiative underscores the government's commitment to advancing clinical research and innovation in vision health, with applications due by January 7, 2027. Interested applicants can find more information and guidance by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-066.html.